UCB Buoyed By Strong First-Half, Lupus Ambitions Undented
This article was originally published in The Pink Sheet Daily
Executive Summary
The Belgian-headquartered company has advanced a second potential lupus drug into clinical trials after disappointing Phase III results with its first, and is monitoring closely the effects of biosimilars in Europe on its marketed TNF-inhibitor Cimzia.